Kansas Patent of the Month – March 2023

CritiTech Inc, experts in the drug development life-cycle, have been granted a patent for their new method of treating cancer which combines local and systemic therapies using antineoplastic particles and an immunotherapeutic agent.

The key to this invention is the use of antineoplastic particles, which are chemotherapeutic particles that can be topically applied directly to the tumor site. The particles are taxane particles between the size of 0.1 microns to 5 microns. Taxane particles include a range of particles such as paclitaxel, docetaxel, and cabazitaxel. Once the antineoplastic particles are topically applied to the tumor site, an immunotherapeutic agent is administered and activated to identify and attack cancer cells.

This method of treatment is highly adaptable, with different delivery methods that can be used depending on the location of the cancer. For instance, pulmonary administration of the antineoplastic particles through nebulization is effective for lung cancer patients with obstructive or restrictive lung disease. Intratumoral injection of the particles is used for solid tumors, such as sarcomas, carcinomas, lymphomas, and head and neck tumors, among others. Finally, intraperitoneal injection of the particles is used for ovarian tumors.

CritiTech’s innovative approach to cancer treatment is a reminder of how science and technology can make a significant impact on the world. It is encouraging to see inventors and scientists working hard to create new ways to treat cancer and other diseases. Who knows what the future holds for cancer treatment, but one thing is for sure: we are on the right path.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts